Health Care · Biotechnology

Roivant Sciences Ltd. ROIV

$34.72-0.29 (-0.83%)delayed quote · as of 2026-07-28 12:34 UTC

Open ROIV in the workspaceCharts, statements, and the evidence behind every figure — free to start.

Market cap

$25.0B

Previous close

$35.01

Volume

3.9M

52-week range

$10.90 – $37.00

Verdictconfidence 58% · moderate

Health stands out; growth and quality flash caution.

1 of 5 dimensions score well; growth and quality flash caution. Value and Momentum not scored — not enough data.

Value—0/2 checks

Growth251/4 checks

Quality00/4 checks

Health1003/3 checks

Momentum—2/2 checks

Every check behind these scores — with its numbers, source, and evidence link — is in the workspace. Free account required.

Key ratioslatest filing FY 2025

Value

P/E TTM

—

P/E FWD

—

EV/EBITDA TTM

—

PEG

—

FCF yield FY2025

-3.0%

Growth

Revenue 3y

−36.0%/yr

Revenue YoY

−71.6%

Expected EPS

—

Quality

Piotroski F

0 / 9

ROIC

ALAN GLOBAL INTELLIGENCE · alanglobalintelligence.comquote as of 2026-07-28 12:34 UTC · fundamentals FY 2025 · SEC EDGAR

Verdict

Reading ROIV’s filed statements…

Continue with ROIV in ALAN

Full evidence trail, financial statements back a decade, valuation history, charts, and alerts.

Open in the workspace Create free account

For information and research only. Not investment advice. ALAN does not place trades or execute orders. Figures come from the sources shown and can lag the market; verify independently before making decisions. Past performance is not predictive of future results.